Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
Thailand Inflation Remains Negative for 10th Straight Month in January 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns 
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
South Korean drugmaker Daewoong Pharmaceutical Co. inked a US$430 million deal to provide US pharmaceutical venture firm Neurogastrx Inc. with its technology for fexuprazan, the novel drug candidate for gastroesophageal reflux.
The technology deal with Neurogastrx made the US the fourth country that the South Korean firm has signed technology deals with, after China, Brazil, and Mexico.
The said countries account for almost 40 percent of the global gastrointestinal disorder market.
The combined value of the deals is already over 1 trillion won.
Daewoong Pharmaceutical will also receive 13.5 percent of Neurogastrx's shares.
Daewoong Pharmaceutical claims that fexuprazan, a class of potassium-competitive acid blockers, exhibited a cure rate of 99 percent during the phase three clinical trials and is expected to win approval from local drug authorities soon.
Neurogastrx is a privately-held biopharmaceutical company that develops therapies for gastrointestinal disorders.
